

Aeterna Zentaris Announces IND Submission by Sinopharm A-Think

Release Date:

Tuesday, June 14, 2016 5:00 pm EDT

Terms:

[Aeterna Zentaris](#) [1] [AEZ](#) [2] [AEZS](#) [3] [CFDA](#) [4] [China Pharmaceutical Company](#) [5] [IND](#) [6] [Sinopharm A-Think](#) [7] [Zoptrex](#) [8]

Dateline City:

CHARLESTON, S.C.

Clinical Development Expected to Start in First Half of 2017

CHARLESTON, S.C.--([BUSINESS WIRE](#) [9])--Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that its licensee, Sinopharm A-Think Pharmaceuticals Co., Ltd. ("Sinopharm A-Think"), which is affiliated with the largest state-owned pharmaceutical company in the People's Republic of China, today submitted an Investigational New Drug application ("IND") for Zoptrex™ to the Chinese State Food and Drug Administration ("CFDA"), remaining on track to commence its clinical program during the first half of 2017.

The IND submission follows Sinopharm A-Think's recent implementation of the processes for manufacturing Zoptrex™, which will enable it to commence its clinical program with product manufactured locally. Dr. Richard Sachse, Senior Vice President and Chief Medical and Scientific Officer of the Company, stated, "The Company's Frankfurt-based personnel assisted Sinopharm A-Think with the IND by providing extensive information regarding the Chemistry, Manufacturing and Controls related to the manufacture of Zoptrex™. We are pleased that we were able to assist our licensee to achieve this important step in their clinical development of Zoptrex™. I remain very impressed by the progress that Sinopharm A-Think is making."

About Aeterna Zentaris Inc.

Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women's health. We are engaged in drug development activities and in the promotion of products for others. We are now conducting Phase 3 studies of two internally developed compounds. The focus of our business development efforts is the acquisition or license of products that are relevant to our therapeutic areas of focus. We also intend to license out certain commercial rights of internally developed products to licensees in territories where such out-licensing would enable us to ensure development, registration and launch of our product candidates. Our goal is to become a growth-oriented specialty biopharmaceutical company by pursuing successful development and commercialization of our product portfolio, achieving successful commercial presence and growth, while consistently delivering value to our shareholders, employees and the medical providers and patients who will benefit from our products. For more information, visit www.aezsinc.com [10].

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the US Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to statements preceded by, followed by, or that include the words "expects," "believes," "intends," "anticipates," and similar terms that relate to future events, performance, or our results. Forward-looking statements involve known and unknown risks and uncertainties that could cause the Company's actual results to differ materially from those in the forward looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects and clinical trials, the successful and timely completion of clinical studies, the risk that safety and efficacy data from any of our Phase 3 trials may not coincide with the data analyses from previously reported Phase 1 and/or Phase 2 clinical trials, the rejection or non-acceptance of any new drug application by one or more regulatory authorities and, more generally, uncertainties related to the regulatory process, the ability of the Company to efficiently commercialize one or more of its products or product candidates, the degree of market acceptance once our products are approved for commercialization, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process, the ability to protect our intellectual property, the potential of liability arising from shareholder lawsuits and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and US securities commissions for additional information on risks and uncertainties relating to forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or by applicable law.

□

Language:

English

Contact:

Aeterna Zentaris Inc.
Philip A. Theodore
Senior Vice President
843-900-3223
ir@aezsinc.com [11]

Ticker Slug:

Ticker: AEZ

Exchange: TSX

ISIN:

CA0079754028

Ticker: AEZS

Exchange: NASDAQ

Source URL: <http://ir.aezsinc.com/press-release/aeterna-zentaris/aeterna-zentaris-announces-ind-submission-sinopharm-think>

Links:

[1] <http://ir.aezsinc.com/category/bw-tag/aeterna-zentaris>

[2] <http://ir.aezsinc.com/category/bw-tag/aez>

[3] <http://ir.aezsinc.com/category/bw-tag/aezs>

[4] <http://ir.aezsinc.com/category/bw-tag/cfda>

[5] <http://ir.aezsinc.com/category/bw-tag/china-pharmaceutical-company>

[6] <http://ir.aezsinc.com/category/bw-tag/ind>

[7] <http://ir.aezsinc.com/category/bw-tag/sinopharm-a-think>

[8] <http://ir.aezsinc.com/category/bw-tag/zoptrex>

[9] <http://www.businesswire.com>

[10] [http://cts.businesswire.com/ct/CT?](http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.aezsinc.com&esheet=51362535&newsiteid=20160614006424&lan=en-US&anchor=www.aezsinc.com&index=1&md5=2c42f6af4bb5177941bb5f5edc45fa5a)

[id=smartlink&url=http%3A%2F%2Fwww.aezsinc.com&esheet=51362535&newsiteid=20160614006424&lan=en-US&anchor=www.aezsinc.com&index=1&md5=2c42f6af4bb5177941bb5f5edc45fa5a](http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.aezsinc.com&esheet=51362535&newsiteid=20160614006424&lan=en-US&anchor=www.aezsinc.com&index=1&md5=2c42f6af4bb5177941bb5f5edc45fa5a)

[11] <mailto:ir@aezsinc.com>